Abstract
Background: Hepatocellular carcinoma (HCC) is among the most prevalent cancers and the second leading cause of cancer-related mortality globally. Objective: The aim was to investigate the sensitivity of sorafenib administration after TACE in advanced HCC patients. Methods: From June 2021 to June 2022, 36 patients from Hayatabad Medical Complex Peshawar were enrolled in this retrospective research. Based on the correct state of liver activity, sorafenib medication was started within two weeks of finishing TACE treatment. Throughout each follow-up, the liver and kidney function, adverse effects, and medicinal impact were assessed using the Modified response assessment criteria in solid tumors (mRECIST). Results: The mean overall survival (mOS) and mean time to progress (mTTP) were 11.5 months and 7.5 months, respectively. Patients with one or more localised hepatic lesions were respectively 18 months and 12 months old (2 = 4.613, P = 0.0314). No patients had a full response, three had partial responses, 11 had stable disease (SD), and 22 had progressive illness (PD), as per the mRECIST. The disease control rate (DCR) was 38.89% (14/36) and the response rate was 8.33% (3/36) for both. Hand-foot skin irritation (21 incidences, 58.3%), and diarrhoea (17 incidences, 47.22%) were the predominant adverse effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
